Philip M. Reaper

7.0k total citations · 2 hit papers
19 papers, 5.4k citations indexed

About

Philip M. Reaper is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Philip M. Reaper has authored 19 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 10 papers in Oncology and 3 papers in Immunology. Recurrent topics in Philip M. Reaper's work include DNA Repair Mechanisms (15 papers), Cell death mechanisms and regulation (8 papers) and Cancer-related Molecular Pathways (7 papers). Philip M. Reaper is often cited by papers focused on DNA Repair Mechanisms (15 papers), Cell death mechanisms and regulation (8 papers) and Cancer-related Molecular Pathways (7 papers). Philip M. Reaper collaborates with scholars based in United Kingdom, United States and Germany. Philip M. Reaper's co-authors include Stephen P. Jackson, Fabrizio d’Adda di Fagagna, Heike Fiegler, Thomas von Zglinicki, Philippa Carr, Gabriele Saretzki, Nigel P. Carter, John R. Pollard, Peter Charlton and Nicola J. Curtin and has published in prestigious journals such as Nature, Nature Communications and Cancer Research.

In The Last Decade

Philip M. Reaper

19 papers receiving 5.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A DNA damage checkpoint response in telomere-initiated senescence

2003 2.1k citations Fabrizio d’Adda di Fagagna, Philip M. Reaper et al. Nature profile →
Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

2004 983 citations Ian Hickson, Yan Zhao et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip M. Reaper United Kingdom	16	4.2k	2.0k	1.7k	721	391	19	5.4k
Marzia Fumagalli Italy	12	2.7k 0.6×	998 0.5×	2.1k 1.3×	611 0.8×	324 0.8×	16	4.4k
Chrysiis Michaloglou United Kingdom	8	3.3k 0.8×	1.4k 0.7×	2.4k 1.4×	810 1.1×	496 1.3×	12	5.5k
Michel M. Ouellette United States	29	2.0k 0.5×	1.4k 0.7×	919 0.5×	488 0.7×	287 0.7×	54	3.5k
Agustin Chicas United States	19	3.4k 0.8×	1.1k 0.6×	990 0.6×	911 1.3×	182 0.5×	20	4.6k
Liesbeth C.W. Vredeveld Netherlands	7	2.4k 0.6×	1.1k 0.5×	1.6k 1.0×	691 1.0×	374 1.0×	7	3.9k
Ross A. Dickins Australia	27	3.3k 0.8×	1.5k 0.7×	966 0.6×	805 1.1×	278 0.7×	44	5.0k
Thomas Kuilman Netherlands	16	3.8k 0.9×	1.9k 1.0×	2.7k 1.6×	1.2k 1.7×	519 1.3×	25	6.7k
Christophe Denoyelle France	24	2.2k 0.5×	1.0k 0.5×	787 0.5×	941 1.3×	499 1.3×	50	3.6k
Jessica E. Bolden Australia	14	3.7k 0.9×	1.2k 0.6×	806 0.5×	448 0.6×	185 0.5×	17	4.9k
Juan Martín‐Caballero Spain	29	1.9k 0.5×	1.4k 0.7×	614 0.4×	376 0.5×	215 0.5×	43	3.0k

Countries citing papers authored by Philip M. Reaper

Since Specialization

Citations

This map shows the geographic impact of Philip M. Reaper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip M. Reaper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip M. Reaper more than expected).

Fields of papers citing papers by Philip M. Reaper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip M. Reaper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip M. Reaper. The network helps show where Philip M. Reaper may publish in the future.

Co-authorship network of co-authors of Philip M. Reaper

This figure shows the co-authorship network connecting the top 25 collaborators of Philip M. Reaper. A scholar is included among the top collaborators of Philip M. Reaper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip M. Reaper. Philip M. Reaper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Zenke, Frank T., Astrid Zimmermann, Heike Dahmen, et al.. (2019). Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy. Cancer Research. 79(13_Supplement). 369–369. 15 indexed citations

2.

Zenke, Frank T., Astrid Zimmermann, Heike Dahmen, et al.. (2019). Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy. 369–369. 1 indexed citations

3.

Knegtel, Ronald M. A., Jean‐Damien Charrier, Steven J. Durrant, et al.. (2019). Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor. Journal of Medicinal Chemistry. 62(11). 5547–5561. 41 indexed citations

4.

Williamson, Chris T., Rowan Miller, Helen N. Pemberton, et al.. (2016). ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nature Communications. 7(1). 13837–13837. 270 indexed citations

5.

Sanjiv, Kumar, Anna Hagenkort, José Manuel Calderón‐Montaño, et al.. (2015). Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. Cell Reports. 14(2). 298–309. 112 indexed citations

6.

Jossé, Rozenn, Scott E. Martin, Rajarshi Guha, et al.. (2014). ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses. Cancer Research. 74(23). 6968–6979. 121 indexed citations

7.

Swan, M.K., Adam Tanner, Philip M. Reaper, et al.. (2014). Structure of human Bloom's syndrome helicase in complex with ADP and duplex DNA. Acta Crystallographica Section D Biological Crystallography. 70(5). 1465–1475. 58 indexed citations

8.

Chen, Tao, et al.. (2014). Development of pharmacodynamic biomarkers for ATR inhibitors. Molecular Oncology. 9(2). 463–472. 15 indexed citations

9.

Hall, Amy B., Yuxin Wang, Diane M. Boucher, et al.. (2014). Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 5(14). 5674–5685. 149 indexed citations

10.

Prevo, Remko, Emmanouil Fokas, Philip M. Reaper, et al.. (2012). The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biology & Therapy. 13(11). 1072–1081. 191 indexed citations

11.

Pires, Isabel M., Monica M. Olcina, Selvakumar Anbalagan, et al.. (2012). Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. British Journal of Cancer. 107(2). 291–299. 127 indexed citations

12.

Fokas, Emmanouil, Remko Prevo, John R. Pollard, et al.. (2012). Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death and Disease. 3(12). e441–e441. 278 indexed citations

13.

Reaper, Philip M., Matthew R. Griffiths, Joanna Long, et al.. (2011). Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nature Chemical Biology. 7(7). 428–430. 476 indexed citations

14.

Charrier, Jean‐Damien, Steven J. Durrant, Julian M.C. Golec, et al.. (2011). Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents. Journal of Medicinal Chemistry. 54(7). 2320–2330. 192 indexed citations

15.

Smits, Veronique A. J., Philip M. Reaper, & Stephen P. Jackson. (2005). Rapid PIKK-Dependent Release of Chk1 from Chromatin Promotes the DNA-Damage Checkpoint Response. Current Biology. 16(2). 150–159. 151 indexed citations

16.

Reaper, Philip M., et al.. (2004). The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes. Oncogene. 23(10). 1911–1921. 40 indexed citations

17.

Reaper, Philip M., Fabrizio d’Adda di Fagagna, & Stephen P. Jackson. (2004). Activation of the DNA Damage Response by Telomere Attrition: A Passage to Cellular Senescence. Cell Cycle. 3(5). 541–544. 45 indexed citations

18.

Hickson, Ian, Yan Zhao, Caroline J. Richardson, et al.. (2004). Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM. Cancer Research. 64(24). 9152–9159. 983 indexed citations breakdown →

19.

Fagagna, Fabrizio d’Adda di, Philip M. Reaper, Heike Fiegler, et al.. (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature. 426(6963). 194–198. 2124 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact